natgillin/translations-raw huggingface dataset:
Darunavir co-administered with cobicistat should not be used in combination with another antiretroviral agent that requires pharmacoenhancement by means of coadministration with an inhibitor of CYP3A4 (see section 4.5).
Darunavir istodobno primijenjen s kobicistatom se ne smije uzimati u kombinaciji s drugim antiretrovirusnim lijekovima koji zahtijevaju farmakokinetičko pojačanje u smislu istodobne primjene s inhibitorom CYP3A4 (vidjeti dio 4.5).
Monitoring of renal function may be indicated when boosted darunavir is given in combination with tenofovir disoproxil, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.
Praćenje funkcije bubrega može biti indicirano kada se pojačani darunavir daje u kombinaciji s tenofovirdizoproksilom, posebno kod bolesnika s podležećom sistemskom ili bubrežnom bolešću ili kod bolesnika koji uzimaju nefrotoksične lijekove.
Nicardipine
Nikardipin
copies/ml) b IAS-USA lists
IAS-USA liste c
Nifedipine
Nifedipin
The overall pharmacokinetic enhancement effect by ritonavir was an approximate 14-fold increase in the systemic exposure of darunavir when a single dose of 600 mg darunavir was given orally in combination with ritonavir at 100 mg twice daily (see section 4.4).
Ukupni učinak pospješenja farmakokinetike ritonavirom bio je približno 14 puta veća sistemska izloženost darunaviru, kad se jednokratna doza od 600 mg darunavira dala peroralno u kombinaciji sa 100 mg ritonavira dva puta na dan (vidjeti dio 4.4).
When used for birth control, alternative methods of non-hormonal contraception are recommended.
Za zaštitu od začeća, preporučuju se drugi oblici nehormonske kontracepcije. - etinilestradiol/drospirenon.
The clinical trial data from ART-experienced patients (TITAN trial and the pooled analysis of the POWER 1, 2 and 3 and DUET 1 and 2 trials) showed that virologic response to darunavir coadministered with low dose ritonavir was decreased when 3 or more darunavir RAMs (V11I, V32I, L33F, I47V, I50V, I54L or M, T74P, L76V, I84V and L89V) were present at baseline or when these mutations developed during treatment.
Podaci kliničkog ispitivanja provedenog među bolesnicima prethodno liječenih ART-om (ispitivanje TITAN i objedinjena analiza ispitivanja POWER 1, 2 i 3 te DUET 1 i 2) pokazali su da je virološki odgovor na darunavir primijenjen istodobno s niskom dozom ritonavira bio smanjen kada su na početku ispitivanja bile prisutne ili su se razvile tijekom liječenja 3 ili više mutacija, povezane s rezistencijom na darunavir (V11I, V32I, L33F, I47V, I50V, I54L ili M, T74P, L76V, I84V i L89V).
For information on cobicistat pharmacokinetic properties, consult the cobicistat Summary of Product Characteristics.
Za informacije o farmakokinetičkim svojstvima kobicistata, pogledajte Sažetak opisa svojstava lijeka za kobicistat.
- if you are allergic to darunavir or any of the other ingredients of this medicine (listed in section 6) or to cobicistat or ritonavir.
- ako ste alergični na darunavir ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.) ili na kobicistat ili ritonavir. - ako imate teške jetrene tegobe.
Lopinavir/ritonavir 533/133.3 mg twice daily lopinavir AUC ↑ 9% lopinavir Cmin ↑ 23% lopinavir Cmax ↓ 2% darunavir AUC ↓ 38%‡
Lopinavir/ritonavir 533/133,3 mg dva puta na dan lopinavir AUC ↑ 9% lopinavir Cmin ↑ 23% lopinavir Cmax ↓ 2% darunavir AUC ↓ 38%‡
- Take darunavir always together with 100 milligram of ritonavir.
- Darunavir uvijek uzimajte zajedno sa 100 miligrama ritonavira.
Viruses selected in these conditions and showing decreased susceptibility to darunavir (range: 23-50-fold) harboured 2 to 4 amino acid substitutions in the protease gene.
Odabrani virusi nisu mogli rasti u prisutnosti darunavira u koncentracijama iznad 400 nM. Virusi odabrani u tim uvjetima, koji su pokazivali smanjenu osjetljivost na darunavir, (raspon: 23-50 puta) pohranili su 2 do 4 aminokiselinskih supstitucija u genu proteaze.
TITAN is a randomised, controlled, open-label Phase III trial comparing darunavir co-administered with ritonavir (600/100 mg twice daily) versus lopinavir/ritonavir (400/100 mg twice daily) in ARTexperienced, lopinavir naïve HIV-1 infected adult patients.
TITAN je randomizirano kontrolirano kliničko ispitivanje otvorenog tipa, faze III pri čemu je uspoređivan darunavir primijenjen istodobno s ritonavirom (600/100 mg dva puta na dan) naspram lopinavira/ritonavira (400/100 mg dva puta na dan) kod odraslih bolesnika inficiranih HIV-1 prethodno liječenih ART-om, ali neliječenih lopinavirom.
≥ 15 kg to < 30 kg
 15 kg do < 30 kg
Clinical monitoring is recommended when co-administering boosted darunavir with these antidepressants and a dose adjustment of the antidepressant may be needed.
Preporučuje se kliničko praćenje kada se ti antidepresivi primjenjuju istodobno s pojačanim darunavirom, a može biti potrebna prilagodba doze antidepresiva.
Darunavir Mylan 400 mg and 800 mg film-coated tablets contain less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free'.
Darunavir Mylan 400 mg and 800 mg filmom obložene tablete sadrže manje od 1 mmol natrija (23 mg) po dozi, tj. zanemarive količine natrija.
Darunavir co-administered with low dose ritonavir should not be used in combination with these medicines.
Darunavir istodobno primijenjen s s niskom dozom ritonavira ne smije se primjenjivati u kombinaciji s ovim lijekovima.
Ritonavir inhibits CYP3A, thereby increasing the plasma concentrations of darunavir considerably.
Ritonavir inhibira CYP3A te na taj način značajno povećava koncentracije darunavira u plazmi.
Darunavir Mylan 75 mg, 150 mg, 300 mg and 600 mg tablets can be used to construct the twice daily 600 mg regimen.
Tablete Darunavir Mylan od 75 mg, 150 mg, 300 mg i 600 mg mogu se primijeniti za dostizanje režima doziranja od 600 mg dva puta na dan.
See the Summary of Product Characteristics for darunavir 75 mg, 150 mg, 300 mg and 600 mg tablets (see section 4.5).
Vidjeti Sažetak opisa svojstava lijeka za darunavir 75 mg, 150 mg, 300 mg i 600 mg tablete (vidjeti dio 4.5).
Baseline genotype or phenotype and virologic outcome Baseline genotype and darunavir FC (shift in susceptibility relative to reference) were shown to be a predictive factor of virologic outcome.
Početni genotip i PV darunavira (promjena u osjetljivosti u odnosu na referentnu vrijednost) pokazali su se predikcijskim faktorima virološkog ishoda.
During the clinical development program (N=2,613 treatment-experienced subjects who initiated therapy with darunavir/ ritonavir 600/100 mg twice daily), 51.3% of subjects experienced at least one adverse reaction.
Tijekom razvojnog kliničkog programa (n=2613 prethodno liječenih ispitanika kod kojih je započela terapija lijekovima darunavir/ritonavir od 600/100 mg dva puta na dan) 51,3% ispitanika doživjelo je najmanje jednu nuspojavu.
During the clinical development program (N=2,613 treatment-experienced subjects who initiated therapy with darunavir/ritonavir 600/100 mg twice daily), 51.3% of subjects experienced at least one adverse reaction.
Tijekom razvojnog kliničkog programa (N=2613 prethodno liječenih ispitanika kod kojih je započela terapija lijekovima darunavir/ritonavir od 600/100 mg dva puta na dan) 51,3% ispitanika doživjelo je najmanje jednu nuspojavu.
Rare headache, peripheral neuropathy, dizziness lethargy, paraesthesia, hypoaesthesia, dysgeusia, disturbance in attention, memory impairment, somnolence syncope, convulsion, ageusia, sleep phase rhythm disturbance
Poremećaji živčanog sustava često manje često rijetko glavobolja, periferna neuropatija, omaglica letargija, parestezija, hipoestezija, disgeuzija, poremećaj pažnje, oštećenje pamćenja, somnolencija sinkopa, konvulzija, ageuzija, poremećaj ritma faza spavanja
It is not recommended to co-administer boosted darunavir with glecaprevir/pibrentasvir.
Ne preporučuje se istodobna primjena pojačani darunavir s glekaprevirom/pibrentasvirom.
- Oestrogen-based hormonal contraceptives and hormonal replacement therapy.
- hormonska kontracepcija na bazi estrogena i hormonska nadomjesna terapija, jer im darunavir može smanjiti učinkovitost.
Co-administration is expected to reduce plasma concentrations of darunavir, ritonavir and cobicistat, which could lead to loss of therapeutic effect and possible development of resistance (see sections 4.4 and 4.5).
Očekuje se da će istodobna primjena sniziti koncentracije darunavira, ritonavira i kobicistata u plazmi, što može dovesti do gubitka terapijskog učinka i mogućeg razvoja rezistencije (vidjeti dijelove 4.4 i 4.5).
C-darunavir with ritonavir dose, approximately 79.5% and 13.9% of the administered dose of
C-darunavira s ritonavirom, približno 79,5% i 13,9% primijenjene doze C-darunavira može se naći u stolici, odnosno mokraći.
Plasma concentrations of these medicinal products may be increased when co-administered with boosted darunavir, resulting in reduced serum cortisol concentrations.
Koncentracija tih lijekova u plazmi može se povećati kada se primjenjuju zajedno s pojačanim darunavirom što dovodi do smanjenih koncentracija kortizola u serumu.
No adjustment of methadone dosage is required when initiating co-administration with darunavir/ritonavir.
Prilagodba doziranja metadona nije potrebna kada se započinje istodobna primjena s darunavirom/ritonavirom.
Monitoring of renal function may be indicated when darunavir coadministered with low dose ritonavir is given in combination with tenofovir disoproxil, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.
Praćenje funkcije bubrega može biti indicirano kada se darunavir istodobno primijenjen s niskom dozom ritonavira, daje u kombinaciji s tenofovir dizoproksilom, posebno kod bolesnika s podležećom sistemskom ili bubrežnom bolešću ili kod bolesnika koji uzimaju nefrotoksične lijekove.
Immune reconstitution inflammatory syndrome
upalni sindrom imunološke rekonstitucije
In addition, pharmacokinetic modeling and simulation of darunavir exposures in paediatric patients across the ages of 3 to < 18 years confirmed the darunavir exposures as observed in the clinical studies and allowed the identification of weight-based darunavir/ritonavir once daily dosing regimens for paediatric patients weighing at least 15 kg that are either ART-naïve or treatment-experienced paediatric patients without DRV-RAMs* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10
Dodatno, farmakokinetičko modeliranje i simulacija izloženosti darunaviru u pedijatrijskih bolesnika u rasponu dobi 3 do < 18 godina potvrdilo je izloženosti darunaviru kako je uočeno u kliničkim ispitivanjima, te je identificiralo režim doziranja za lijekove darunavir/ritonavir temeljen na težini jednaput na dan za pedijatrijske bolesnike težine najmanje 15 kg koji prethodno nisu liječeni ART-om ili za prethodno liječene pedijatrijske bolesnike koji nemaju DRV-RAM* a imaju plazmatsku HIV-1 RNK < 100 000 kopija/ml i broj CD4+ stanica ≥ 100 stanica x 10
- Take darunavir always together with 150 milligram of cobicistat or 100 milligram of ritonavir.
- Darunavir uvijek uzimajte zajedno sa 150 miligrama kobicistata ili 100 miligrama ritonavira.
The overall pharmacokinetic enhancement effect by ritonavir was an approximate 14-fold increase in the systemic exposure of darunavir when a single dose of 600 mg darunavir was given orally in combination with ritonavir at 100 mg twice daily.
Ukupni učinak ritonavira kao farmakokinetičkog pojačivača očitovao se u približno 14 puta većoj sistemskoj izloženosti darunaviru kada se primijeni jednokratna peroralna doza od 600 mg darunavira u kombinaciji sa 100 mg ritonavira dva puta na dan.
Indinavir 800 mg twice daily indinavir AUC ↑ 23% indinavir Cmin ↑ 125% indinavir Cmax ↔ #darunavir AUC ↑ 24% darunavir Cmin ↑ 44% #darunavir Cmax ↑ 11%
Indinavir 800 mg dva puta na dan indinavir AUC ↑ 23% indinavir Cmin ↑ 125% indinavir Cmax ↔ #darunavir AUC ↑ 24% darunavir Cmin ↑ 44% #darunavir Cmax ↑ 11%
Plasma concentrations of these medicinal products may be increased when co-administered with darunavir with low dose ritonavir, resulting in reduced serum cortisol concentrations.
Koncentracija tih lijekova u plazmi može se povećati kada se primjenjuju istodobno s darunavirom s niskom dozom ritonavira što dovodi do smanjenih koncentracija kortizola u serumu.
An increase of systemic exposure to darunavir was observed when darunavir coadministered with 100 mg ritonavir was co-administered with rifabutin (150 mg once every other day).
Povišena sistemska izloženost darunaviru primijećena je kada je darunavir istodobno primijenjen sa 100 mg ritonavira i rifabutinom (150 mg jedanput svaki drugi dan).
Film-coated tablets
Filmom obložena tableta
ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR Apixaban
ANTIKOAGULANS/INHIBITOR AGREGACIJE TROMBOCITA
Uncommon increased alanine aminotransferase hepatitis, cytolytic hepatitis, hepatic steatosis, hepatomegaly, increased transaminase, increased aspartate aminotransferase, increased blood bilirubin, increased blood alkaline phosphatase, increased gamma-glutamyltransferase
Poremećaji jetre i žuči često manje često povišena alanin aminotransferaza hepatitis, citolitički hepatitis, hepatička steatoza, hepatomegalija, povišene transaminaze, povišena aspartat aminotransferaza, povišen bilirubin u krvi, povišena alkalna fosfataza u krvi, povišena gama-glutamiltransferaza
CD4+ cell count mean change from baseline (x 106/l)b c c a
CD4+ stanica od početne vrijednosti (x 106/l)e a
copies/ml at the week-8; rebound: HIV-1 RNA < 50 copies/ml followed by confirmed HIV-1 RNA to ≥ 400 copies/ml or confirmed > 1 log10 HIV-1 RNA increase from the nadir; discontinuations with HIV-1 RNA ≥ 400 copies/ml at last visit b IAS-USA lists c In GS-US216-130 baseline phenotype was not available
Virološki neuspjeh definiran je kao: nikad suprimiran: potvrđena HIV-1 RNK < 1 log10 smanjenje u odnosu na početnu vrjednost i ≥ 50 kopija/ml u 8.tjednu; povratak: HIV-1 RNK < 50 kopija/ml nakon čega slijedi potvrđena HIV-1 RNK do ≥ 400 kopija/ml ili potvrđeni > 1 log10 HIV-1 RNK porast u odnosu na najnižu točku (od engl.nadir); prekid liječenja sa HIV-1 RNK ≥ 400 kopija/ml pri zadnjoj posjeti b
No dose adjustment for darunavir/ritonavir is recommended.
Ne preporučuje se prilagodba doze darunavira/ritonavira.
With Baseline HIV-1 RNA (copies/ml)
S početnom HIV-1 RNK (kopija/ml)
The evidence of efficacy of darunavir co-administered with ritonavir (600/100 mg twice daily) in ART-experienced patients is based on the 96 weeks analysis of the Phase III trial TITAN in ART-experienced lopinavir naïve patients, on the 48 week analysis of the Phase III trial ODIN in ART-experienced patients with no DRV-RAMs, and on the analyses of 96 weeks data from the Phase IIb trials POWER 1 and 2 in ART-experienced patients with high level of PI resistance.
Dokaz djelotvornosti darunavira primijenjenog istodobno s ritonavirom (600/100 mg dva puta na dan) u bolesnika prethodno liječenih ART-om temelje se na analizi podataka dobivenih nakon 96 tjedana liječenja u ispitivanju TITAN faze III u bolesnika prethodno liječenih ART-om, a neliječenih lopinavirom, na analizi podataka dobivenih nakon 48 tjedana liječenja u ispitivanju ODIN faze III u bolesnika prethodno liječenih ART-om bez DRV RAM, i analizama podataka dobivenih nakon
Atorvastatin 10 mg once daily atorvastatin AUC ↑ 3-4 fold atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin Cmax ↑ ≈2 fold darunavir/ritonavir
Atorvastatin 10 mg jedanput na dan atorvastatin AUC ↑ 3-4 puta atorvastatin Cmin ↑ ≈5,5-10 puta atorvastatin Cmax ↑ ≈2 puta #darunavir/ritonavir
The interaction trial showed a comparable daily systemic exposure for rifabutin between treatment at 300 mg once daily alone and 150 mg once every other day in combination with darunavir/ritonavir (600/100 mg twice daily) with an about 10-fold increase in the daily exposure to the active metabolite 25O-desacetylrifabutin.
Ispitivanje interakcije pokazalo je usporedivu dnevnu sistemsku izloženost za rifabutin između liječenja s 300 mg jedanput na dan samostalno i 150 mg jedanput svaki drugi dan u kombinaciji s darunavirom/ritonavirom (600/100 mg dva puta na dan) uz oko 10 puta veću dnevnu izloženost aktivnom metabolitu 25-O-desacetilrifabutinu.
Your doctor should do blood tests before you start darunavir.
Prije započinjanja darunavira liječnik Vam treba napraviti krvne pretrage.
Darunavir Mylan 75 mg film-coated tablets are available in blister packs containing 480 tablets and in plastic bottles containing 480 tablets.
Darunavir Mylan 75 mg filmom obložene tablete dostupne su u blister pakiranjima koja sadržavaju 480 tableta i plastičnim bocama koje sadržavaju 480 tableta.
In an interaction study #, a comparable systemic exposure to sildenafil was observed for a single intake of 100 mg sildenafil alone and a single intake of 25 mg sildenafil co-administered with darunavir and low dose ritonavir.
#, primijećena je usporediva sistemska izloženost sildenafilu unosom jednokratne doze od 100 mg samo sildenafila i unosa jednokratne doze od 25 mg sildenafila istodobno primijenjenog s darunavirom i niskom dozom ritonavira.
The steady-state pharmacokinetic parameters of darunavir were comparable when boosted with cobicistat versus ritonavir.
Farmakokinetički parametri darunavira pojačanog s kobicistatom u stanju dinamičke ravnoteže bili su usporedivi s ritonavirom.
Lopinavir/ ritonavir 800/200 mg per day N=346
Lopinavir/ ritonavir 800/200 mg na dan n=346
Dose adjustment for buprenorphine may not be necessary when coadministered with boosted darunavir but a careful clinical monitoring for naloxone Cmax ↔
Prilagodba doze buprenorfina možda neće biti potrebna kada se primjenjuje istodobno s pojačanim darunavirom, ali se preporučuje pažljivo kliničko praćenje znakova opijatne toksičnosti.
No new safety findings were identified in the 192 week analysis of the treatment-naïve subjects in which the mean treatment duration of darunavir/ ritonavir 800/100 mg once daily was 162.5 weeks.
U 192 tjednoj analizi nije bilo novih sigurnosnih nalaza u prethodno neliječenih ispitanika, a u kojih je srednja vrijednost trajanja liječenja darunavirom/ritonavirom od 800/100 mg jednaput na dan bila 162,5 tjedna.
Voriconazole should not be combined with darunavir coadministered with low dose ritonavir unless an assessment of the benefit/risk ratio justifies the use of voriconazole.
Vorikonazol se ne smije kombinirati s darunavirom istodobno primijenjenim s niskom dozom ritonavira, osim ako se procijeni da omjer koristi i rizika opravdava primjenu vorikonazola.
Clinical monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with darunavir with low dose ritonavir.
Preporučeno je kliničko praćenje terapijskih učinaka i nuspojava kada se ovi lijekovi primjenjuju istodobno s darunavirom s niskom dozom ritonavira.
HDPE bottle pack This medicinal product does not require any special storage conditions.
Boca od polietilena visoke gustoće (HDPE) Lijek ne zahtijeva posebne uvjete čuvanja.
● 21 ART-experienced HIV-1 infected paediatric patients aged from 3 to < 6 years and weighing 10 kg to < 20 kg (16 participants from 15 kg to < 20 kg) who received darunavir oral suspension with low dose ritonavir twice daily in combination with other antiretroviral agents.
● 21 pedijatrijski bolesnik u dobi od 3 do < 6 godina i težine od 10 kg do < 20 kg (16 ispitanika imalo je od 15 kg do < 20 kg), prethodno liječeni ART-om, a inficirani su virusom HIV-1 te su primali darunavir oralnu suspenziju s niskom dozom ritonavira dva puta na dan u kombinaciji s drugim antiretrovirusnim lijekovima.
If parenteral midazolam is coadministered with darunavir coadministered with low dose ritonavir it may cause a large increase in the concentration of this benzodiazepine.
Ako se parenteralni midazolam istodobno primjenjuje s darunavirom istodobno primijenjenim s niskom dozom ritonavira, to može izazvati velik porast koncentracija ovog benzodiazepina.
HIV Protease inhibitors (PIs) - with co-administration of low dose ritonavir† Lopinavir/ritonavir
Inhibitori Proteaze (IP) HIV-a - uz istodobnu primijenu niske doze ritonavira † Lopinavir/ritonavir
300 mg once daily atazanavir AUC ↔ atazanavir Cmin ↑ 52% atazanavir Cmax ↓ 11% #darunavir AUC ↔ darunavir Cmin ↔ #darunavir Cmax ↔
300 mg jedanput na dan atazanavir AUC ↔ atazanavir Cmin ↑ 52% atazanavir Cmax ↓ 11% #darunavir AUC ↔ darunavir Cmin ↔ #darunavir Cmax ↔
Darunavir must be taken in combination with a low dose of ritonavir and other anti-HIV medicines.
Darunavir se mora uzimati u kombinaciji s niskom dozom ritonavira i drugim lijekovima protiv HIVa.
Caution is warranted and therapeutic concentration monitoring, if available, is recommended for these antiarrhythmics when coadministered with darunavir with low dose ritonavir.
Nužan je oprez, te ako je dostupno, preporučuje se praćenje terapijskih koncentracija za ove antiaritmike kada se primjenjuje istodobno s darunavirom s niskom dozom ritonavira.
Immune system disorders Uncommon immune reconstitution inflammatory syndrome, (drug) hypersensitivity
Poremećaji imunološkog sustava manje često upalni sindrom imunološke rekonstitucije, preosjetljivost (na lijek)
Common side effects (may affect up to 1 in 10 people) - vomiting, nausea, abdominal pain or distension, dyspepsia, flatulence - headache, tiredness, dizziness, drowsiness, numbness, tingling or pain in hands or feet, loss of strength, difficulty falling asleep.
Česte nuspojave (mogu se javiti u do 1 na 10 osoba) - povraćanje, mučnina, bol u trbuhu ili nadimanje trbuha, probavne tegobe, vjetrovi - glavobolja, umor, omaglica, omamljenost, utrnulost, trnci ili bolovi u šakama ili stopalima,
Instructions for children 3 years of age and above, weighing more than 40 kilograms - Take 800 milligram darunavir (2 tablets containing 400 milligram of darunavir or 1 tablet containing 800 milligram of darunavir) at the same time, once a day, every day.
Upute za djecu od 3 godine i više, težine najmanje 40 kilograma - Uzmite 800 miligrama darunavira (2 tablete koja sadrže 400 miligrama darunavira ili 1 tableta koja sadrži 800 miligrama darunavira ) u isto vrijeme, jedanput na dan, svaki dan.
HIV-1 RNA < 50 copies/mla CD4+ percent change from baseline b
HIV-1 RNK < 50 kopija/mla Postotak promjene CD4+ od početne vrijednosti b
Caution is warranted and ther apeutic concentration monitoring, if available, is recommended for these antiarrhythmics when co-administered with boosted darunavir.
Nužan je oprez, te ako je dostupno, preporučuje se praćenje terapijskih koncentracija za ove antiaritmike kada se primjenjuju istodobno s pojačanim darunavirom.
Concomitant administration of darunavir with low dose ritonavir and quetiapine is contraindicated as it may increase quetiapinerelated toxicity.
Istodobna primjena darunavira s niskom dozom ritonavira i kvetiapina je kontraindicirana jer može povisiti toksičnost povezanu s kvetiapinom.
tenofovir AUC ↑ 22% tenofovir Cmin ↑ 37% tenofovir Cmax ↑ 24% #darunavir AUC ↑ 21% darunavir Cmin ↑ 24% #darunavir Cmax ↑ 16% (↑ tenofovir from effect on MDR-1 transport in the renal tubules)
tenofovir AUC ↑ 22% tenofovir Cmin ↑ 37% tenofovir Cmax ↑ 24% #darunavir AUC ↑ 21% darunavir Cmin ↑ 24% #darunavir Cmax ↑ 16% (↑tenofovira zbog učinka na transport putem MDR-1 u bubrežnim tubulima)
see section 4.5) - sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil - simvastatin, lovastatin and lomitapide (see section 4.5) - dabigatran, ticagrelor (see section 4.5).
- triazolam, peroralno primijenjen midazolam (mjere opreza za parenteralnu primjenu midazolama, vidjeti dio 4.5) - sildenafil - kada se primjenjuje za liječenje plućne arterijske hipertenzije, avanafil - simvastatin, lovastatin i lomitapid (vidjeti dio 4.5) - dabigatran, tikagrelor (vidjeti dio 4.5).
Darunavir Mylan must always be given orally with low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products.
Darunavir Mylan uvijek se mora primjenjivati peroralno s niskom dozom ritonavira kao farmakokinetičkim pojačivačem i u kombinaciji s drugim antiretrovirusnim lijekovima.